Understanding how blood clots and stops bleeding
Hemostasis and Thrombosis: Chemistry, Biology and Physiology
['FUNDING_P01'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11193778
This program looks at how the proteins and membrane complexes that make blood clot work and designs reversible RNA-based blockers that might help control harmful clots.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11193778 on ClinicalTrials.gov |
What this research studies
This research looks at the proteins and membrane complexes that make blood clot and why they sometimes cause disease. One project focuses on how the prothrombinase complex activates clotting proteins, another examines how factor V becomes the active helper factor Va, and a third is designing reversible RNA aptamer blockers that link two binding parts to potently but temporarily block clotting enzymes. Most work is done in the lab with purified human proteins, membrane models, biochemical tests, and structural methods to reveal molecular mechanisms. If you donate blood samples or join related clinical protocols in the future, your participation could help turn these lab findings into new treatments.
Who could benefit from this research
Good fit: People with bleeding disorders, a history of thrombosis, or those willing to donate blood samples for research would be the most relevant participants.
Not a fit: People without clotting-related conditions or those seeking immediate clinical treatment are unlikely to receive direct benefit from this lab-based program.
Why it matters
Potential benefit: If successful, this work could lead to safer, reversible therapies to prevent or treat harmful blood clots and improve understanding of bleeding disorders.
How similar studies have performed: Previous laboratory and early-phase clinical work has shown RNA aptamers can target clotting proteins, but the specific bivalent exosite-plus-active-site RNA blocker approach here is newer and experimental.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRISHNASWAMY, SRIRAM — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: KRISHNASWAMY, SRIRAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.